XNAS · Healthcare · Biotechnology
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.63 | -0.84 | -33.33% | $194.5M | ❌ Miss | +0.83% | +3.28% | — |
| 2026-02-24 | Q4 2025 | -0.67 | -1.00 | -49.25% | $154.2M | ❌ Miss | +3.57% | -5.53% | +6.25% |
| 2025-10-29 |
| Q3 2025 |
| -0.82 |
| -0.95 |
| -15.85% |
| $120.7M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | -0.68 | -0.95 | -39.71% | $110.6M | ❌ Miss | -12.86% | -0.24% | +5.32% |
| 2025-02-20 | Q4 2024 | -1.09 | -1.40 | -28.44% | $5.9M | ❌ Miss | +0.12% | -6.94% | +1.13% |
| 2024-11-12 | Q3 2024 | -0.98 | -0.86 | +12.24% | $2.7M | ✅ Beat | +0.69% | -8.45% | +12.39% |
| 2024-08-01 | Q2 2024 | -1.04 | -1.06 | -1.92% | $2.2M | ❌ Miss | +0.00% | -6.49% | +9.78% |
| 2024-05-02 | Q1 2024 | -0.89 | -0.20 | +77.53% | $211.1M | ✅ Beat | +0.32% | +3.57% | +4.47% |
Showing last 8 quarters.